Impact of alemtuzumab treatment on the survival and function of human regulatory T cellsin vitro

T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10

(2013) Esther Bandala-Sanchez et al.   NATURE IMMUNOLOGY

Altered frequency of T regulatory cells is associated with disability status in relapsing–remitting multiple sclerosis patients

(2012) Lasse Bjerg et al.   JOURNAL OF NEUROIMMUNOLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Alemtuzumab more effective than interferon  -1a at 5-year follow-up of CAMMS223 Clinical Trial

(2012) A. J. Coles et al.   NEUROLOGY

Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis

(2012) Sambasiva P. Rao et al.   PLoS One

Anti-CD3 Therapy Promotes Tolerance by Selectively Depleting Pathogenic Cells while Preserving Regulatory T Cells

(2011) C. Penaranda et al.   JOURNAL OF IMMUNOLOGY

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

(2011) Grant A Hill-Cawthorne et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes

(2011) Tri-Hung Nguyen et al.   LEUKEMIA & LYMPHOMA

T Regulatory Cells Are Markers of Disease Activity in Multiple Sclerosis Patients

(2011) Dacia Dalla Libera et al.   PLoS One

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

(2010) Joanne L. Jones et al.   BRAIN

ANTI-CD3 therapy expands the numbers of CD4+ and CD8+ treg cells and induces sustained amelioration of collagen-induced arthritis

(2009) Clare A. Notley et al.   ARTHRITIS AND RHEUMATISM

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy

(2009) Liuyan Jiang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model

(2009) Yanping Hu et al.   IMMUNOLOGY

CD39+Foxp3+ Regulatory T Cells Suppress Pathogenic Th17 Cells and Are Impaired in Multiple Sclerosis

(2009) J. M. Fletcher et al.   JOURNAL OF IMMUNOLOGY

CD4+CD25+FOXP3+Regulatory T Cells Increase De Novo in Kidney Transplant Patients After Immunodepletion with Campath-1H

(2008) D. D. Bloom et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Mechanisms of regulatory T-cell suppression – a diverse arsenal for a moving target

(2008) Dorothy K. Sojka et al.   IMMUNOLOGY

Multiple Sclerosis and Regulatory T Cells

(2008) Cristina Maria Costantino et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

(2008) Clive S. Zent et al.   LEUKEMIA RESEARCH

A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions

(2008) C. Grutter et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The role of regulatory T cells in multiple sclerosis

(2008) Alla L Zozulya et al.   Nature clinical practice. Neurology